RxDoctor Payments Data

Ariane Abadi, PA

Physician Assistant · Philadelphia, PANPI 1619641685

Payments from drug & device makers

$1,243in general payments, 2019–2025

Across 26 payments — averaging $47.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Impulse Dynamics (USA) Inc.$317
  • E.r. Squibb & Sons, L.L.C.$164
  • Bridgebio Pharma, Inc.$150
  • AstraZeneca$120
  • Merck$120
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$117
  • plus $255 from 5 others

What the payments were for

  • Food & beverage$1,243100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,243 in reported general payments places this provider in the 80th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$5,055
Medicare patients
32
Services billed
78

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis34$799,704
FarxigaDapagliflozin Propanediol187$177,206
EntrestoSacubitril/Valsartan148$174,863
EliquisApixaban113$104,855
JardianceEmpagliflozin56$69,553
XareltoRivaroxaban15$14,513
Metoprolol Succinate153$3,328
Atorvastatin Calcium210$2,625
Valsartan59$1,585
Potassium Chloride49$1,457
Ranolazine ErRanolazine11$1,404
Spironolactone167$1,358
Bumetanide45$1,332
Hydralazine Hcl109$1,266
Rosuvastatin Calcium39$1,187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$58$904,560147 claims
AstraZenecaFarxiga$120$177,206187 claims
Boehringer IngelheimJardiance$108$69,55356 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →